Suppr超能文献

白细胞介素25(IL-25)在胆管癌中的表达。

Interleukin 25 (IL-25) expression in cholangiocarcinoma.

作者信息

Kaewsarabhumi Supakit, Proungvitaya Tanakorn, Limpaiboon Temduang, Tippayawat Patcharaporn, Tummanatsakun Doungdean, Titapun Attapol, Sa-Ngaimwibool Prakasit, Proungvitaya Siriporn

机构信息

Centre of Research and Development of Medical Diagnostic Laboratories (CMDL), Faculty of Associated Medical Sciences, Khon Kaen University, Khon Kaen 40002, Thailand.

Cholangiocarcinoma Research Institute (CARI), Faculty of Medicine, Khon Kaen University, Khon Kaen 40002, Thailand.

出版信息

Mol Clin Oncol. 2020 Dec;13(6):84. doi: 10.3892/mco.2020.2154. Epub 2020 Oct 15.

Abstract

Various cytokines are involved in carcinogenesis and tumor progression. Some tumor cells produce cytokines by themselves. Using secretome analysis, a high expression of APEX-1 was found in cholangiocarcinoma (CCA) cell lines. During this secretome analysis, it was found that CCA cell lines overexpressed some cytokines and related molecules, including interleukin 25 (IL-25). In the present study, we first performed precise secretome analysis on cytokines and related molecules in CCA cell lines and identified that IL-25 was overexpressed in CCA cell lines. Then, using immunohistochemical methods, we investigated the expression of IL-25 in the cancer tissues from 20 CCA patients in Northeast Thailand. Correlation between IL-25 expression levels and patients' clinical parameters were analyzed. The results showed that IL-25 expression was significantly (P<0.0001) higher in cancerous tissues than in the normal bile ducts and in the adjacent tissues. Overexpression of IL-25 protein in CCA tissue was confirmed using western blot analysis. Moreover, IL-25 expression in cancerous tissues was significantly (P<0.0015) higher in CCA patients with metastasis than in CCA patients without metastasis. Survival analysis revealed that a high expression of IL-25 was correlated with shorter survival time of CCA patients (P=0.0260). Aberrant expression of IL-25 in CCA tissue was associated with tumor metastasis and poor prognosis, suggesting that IL-25 is a potential prognostic biomarker. Biological roles of IL-25 in CCA genesis and progression should be explored in future.

摘要

多种细胞因子参与致癌作用和肿瘤进展。一些肿瘤细胞自身会产生细胞因子。通过分泌蛋白质组分析,发现APEX - 1在胆管癌(CCA)细胞系中高表达。在这项分泌蛋白质组分析过程中,发现CCA细胞系过表达一些细胞因子和相关分子,包括白细胞介素25(IL - 25)。在本研究中,我们首先对CCA细胞系中的细胞因子和相关分子进行了精确的分泌蛋白质组分析,并确定IL - 25在CCA细胞系中过表达。然后,我们采用免疫组化方法,研究了泰国东北部20例CCA患者癌组织中IL - 25的表达情况。分析了IL - 25表达水平与患者临床参数之间的相关性。结果显示,癌组织中IL - 25的表达显著高于正常胆管组织和癌旁组织(P<0.0001)。通过蛋白质免疫印迹分析证实了CCA组织中IL - 25蛋白的过表达。此外,有转移的CCA患者癌组织中IL - 25的表达显著高于无转移的CCA患者(P<0.0015)。生存分析显示,IL - 25高表达与CCA患者较短的生存时间相关(P = 0.0260)。CCA组织中IL - 25的异常表达与肿瘤转移和预后不良相关,提示IL - 25是一种潜在的预后生物标志物。未来应探索IL - 25在CCA发生和进展中的生物学作用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d8a4/7642803/00e45bacdc90/mco-13-06-02154-g00.jpg

相似文献

1
Interleukin 25 (IL-25) expression in cholangiocarcinoma.
Mol Clin Oncol. 2020 Dec;13(6):84. doi: 10.3892/mco.2020.2154. Epub 2020 Oct 15.
3
Aberrant expression of GATA binding protein 6 correlates with poor prognosis and promotes metastasis in cholangiocarcinoma.
Eur J Cancer. 2013 May;49(7):1771-80. doi: 10.1016/j.ejca.2012.12.015. Epub 2013 Jan 11.
4
CAPS1 Suppresses Tumorigenesis in Cholangiocarcinoma.
Dig Dis Sci. 2020 Apr;65(4):1053-1063. doi: 10.1007/s10620-019-05843-9. Epub 2019 Sep 27.
5
The Prognostic Role of SOCS3 and A20 in Human Cholangiocarcinoma.
PLoS One. 2015 Oct 20;10(10):e0141165. doi: 10.1371/journal.pone.0141165. eCollection 2015.
6
Significance of S100P as a biomarker in diagnosis, prognosis and therapy of opisthorchiasis-associated cholangiocarcinoma.
Int J Cancer. 2016 Jan 15;138(2):396-408. doi: 10.1002/ijc.29721. Epub 2015 Aug 27.
7
8
YKL-40/chitinase-3-like protein 1 is associated with poor prognosis and promotes cell growth and migration of cholangiocarcinoma.
Tumour Biol. 2016 Jul;37(7):9451-63. doi: 10.1007/s13277-016-4838-z. Epub 2016 Jan 19.
9
STATs profiling reveals predominantly-activated STAT3 in cholangiocarcinoma genesis and progression.
J Hepatobiliary Pancreat Sci. 2014 Oct;21(10):767-76. doi: 10.1002/jhbp.131. Epub 2014 Jul 16.
10
NQO1 expression correlates with cholangiocarcinoma prognosis.
Asian Pac J Cancer Prev. 2012;13 Suppl:131-6.

引用本文的文献

1
Role of interleukins in the pathogenesis of cholangiocarcinoma: A literature review.
World J Gastrointest Oncol. 2025 Jul 15;17(7):107341. doi: 10.4251/wjgo.v17.i7.107341.
2
The IL-17 family in diseases: from bench to bedside.
Signal Transduct Target Ther. 2023 Oct 11;8(1):402. doi: 10.1038/s41392-023-01620-3.
3
Interleukin 25 and its biological features and function in intestinal diseases.
Cent Eur J Immunol. 2022;47(4):362-372. doi: 10.5114/ceji.2022.124416. Epub 2023 Jan 31.
4
Interleukin-25: New perspective and state-of-the-art in cancer prognosis and treatment approaches.
Cancer Med. 2021 Aug;10(15):5191-5202. doi: 10.1002/cam4.4060. Epub 2021 Jun 15.

本文引用的文献

2
Innate lymphoid cells in organ fibrosis.
Cytokine Growth Factor Rev. 2018 Aug;42:27-36. doi: 10.1016/j.cytogfr.2018.07.002. Epub 2018 Jul 30.
4
Biomarkers for the Diagnosis of Cholangiocarcinoma: A Systematic Review.
Am J Trop Med Hyg. 2018 Jun;98(6):1788-1797. doi: 10.4269/ajtmh.17-0879. Epub 2018 Apr 5.
5
A pathology atlas of the human cancer transcriptome.
Science. 2017 Aug 18;357(6352). doi: 10.1126/science.aan2507.
6
Cholangiocarcinoma: Current Knowledge and New Developments.
Gut Liver. 2017 Jan 15;11(1):13-26. doi: 10.5009/gnl15568.
7
IL-25 blockade inhibits metastasis in breast cancer.
Protein Cell. 2017 Mar;8(3):191-201. doi: 10.1007/s13238-016-0345-7. Epub 2016 Dec 1.
8
The Role of Interleukin-17 in Lung Cancer.
Mediators Inflamm. 2016;2016:8494079. doi: 10.1155/2016/8494079. Epub 2016 Oct 30.
9
Immunohistochemistry for Pathologists: Protocols, Pitfalls, and Tips.
J Pathol Transl Med. 2016 Nov;50(6):411-418. doi: 10.4132/jptm.2016.08.08. Epub 2016 Oct 13.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验